Brought to you by 
Optimer gets $32.9mm via direct offering
24 Mar 2009
Executive Summary
Anti-infectives company Optimer Pharmaceuticals grossed $32.9mm through a registered direct offering of 2.79mm common shares priced at $10 each (an 8% discount) to institutional investors. The company also sold 457,666 units at $10.93 apiece (a 4% premium) to ProQuest Investments; each unit consists of one common share and one five-year warrant to buy one-fifth of a common share at the same price.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Synthesis Technologies, Production Processes
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Optimer gets $32.9mm via direct offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice